Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, single-center, randomized study to evaluate the effect of sarpogrelate, a selective serotonin receptor antagonist, and high dose statin on the reduction of coronary spasm in the patients with variant angina

Trial Profile

A prospective, single-center, randomized study to evaluate the effect of sarpogrelate, a selective serotonin receptor antagonist, and high dose statin on the reduction of coronary spasm in the patients with variant angina

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Atorvastatin (Primary) ; Sarpogrelate (Primary) ; Simvastatin
  • Indications Arterial occlusive disorders; Variant angina pectoris
  • Focus Therapeutic Use
  • Acronyms ANPLAG
  • Most Recent Events

    • 09 Feb 2018 Planned End Date changed from 1 Feb 2016 to 31 Dec 2018.
    • 09 Feb 2018 Planned primary completion date changed from 1 Aug 2015 to 31 Dec 2018.
    • 20 Oct 2014 Planned End Date changed from 1 Feb 2015 to 1 Feb 2016 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top